InnoCare announces priority review of orelabrutinib for the treatment of relapsed or refractory marginal zone lymphoma by NMPA

InnoCare Pharma

6 September 2022 - InnoCare Pharma announced today that BTK inhibitor orelabrutinib has been granted priority review for the treatment of relapsed or refractory marginal zone lymphoma by the Center for Drug Evaluation of the China National Medical Products Administration, which accepted the supplemental new drug pplication of orelabrutinib for the treatment of R/R MZL recently.

Read InnoCare Pharma press release

Michael Wonder

Posted by:

Michael Wonder